Browse press releases
The newest releases come first, each with its full text here and a link to its original. Try the filters to narrow them down.
- 从技术并跑到落地困境，中国基因治疗的商业突围之路当前，基因治疗正站在一个尴尬的节点上：技术能力在加速，而支付与监管能力正在成为一个新的瓶颈。 2026年，基因治疗的全球图景呈现明显的“两极分化”。在美国和欧洲，基因治疗的适应症持续扩展：美国食品药品监督管理局（FDA）将基因疗法Casgevy的适用年龄下调至2岁；欧盟批准了Itvisma覆盖更广泛的脊髓性肌萎缩症（SMA）人群。2026年8月，FDA批准了十余年来首个新的溶瘤病毒疗法Tudriqev。不过，在中国，基因治疗的商业化落地仍举步维艰。 “我们的产品发了两篇顶刊论文，不是因为药物质量不好，是因为没有人能够支付。”在近期举行的2026中国细胞与基因治疗（CSGCT）大会上，信念医药联合创始人肖啸在圆桌讨论中表示，信念医药花了近一年半时间，才完成第一例患者用药的价格谈判，“30万元在中国标准来说是高的，但在欧美标准却是低的。” 这无疑是一个结构性困境。中国基因治疗在技术层面已经完成了从“跟跑”到“并跑”的跨越：9款CAR
- Annovis Announces Partnership with Weave Bio, AI Regulatory Platform, in Preparation of NDA for Buntanetap in Alzheimer’s DiseaseAnnovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a Phase 3 clinical-stage biotechnology company developing the investigational oral therapy, buntanetap, for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced a collaboration with Weave Bio, an AI platform for regulatory content and knowledge management, in support of the planned New Drug Application (NDA) for buntanetap.
- BioAro Launches AI-Assisted LONgevity+™ Bioactives in the U.S. and U.K.BioAro launches LONgevity+™ bioactives in the US and UK, combining AI-assisted research, precision health, wellness and personalization.
- Altimmune, IncAltimmune to Participate in Stifel Cardiometabolic ForumAltimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that management will participate in a fireside chat at the Stifel 2026 Virtual Cardiometabolic Forum on Wednesday, September 30, 2026, at 10:30 a.m. ET.
- MeiraGTx LONDON andMeiraGTx Appoints Accomplished Healthcare Portfolio Manager Alan M. Sebulsky to Board of DirectorsMeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced the appointment of Alan M. Sebulsky to its Board of Directors.
- OpenAIIntroducing MentalHealthBenchCompanies: OpenAIMentalHealthBench is an expert-informed benchmark for evaluating helpful and safe AI responses across realistic mental health conversations.
- NYO3 Signs Letter of Intent to Acquire Norway's Understory Factory and Oslo Flagship Store Opens in Parallel to Accelerate Global ExpansionOn September 21 (local time), NYO3, a Norwegian premium anti-aging supplement brand, and Aker BioMarine, the global krill raw material giant, signed a letter of intent for a wholly-owned acquisition of the Understory factory in Oslo. NYO3 Norwegian flagship store officially opened on the same day. The implementation of two major moves—the acquisition and the store opening—marks that NYO3 will leverage Norway’s high-standard local manufacturing capabilities to continuously advance its global layout in the health industry.
- Rechargeable Thin Film Battery Market Outlook 2026-2035 - Featuring Profiles of Leading Companies Cymbet, Ilika, and ITENWearables, IoT and Medical Devices Drive Rechargeable Thin Film Battery Opportunities as Solid-State Innovation Accelerates
- Urinary Tract Obstruction Treatment Devices Market Set for Growth Through 2034, Fueled by Minimally Invasive Innovation and Rising Patient DemandRising urological disease is driving demand for catheters and minimally invasive devices, creating opportunities in smart products, AI-enabled care and North America.
- Obesity Treatment Landscape 2026: Obesity Competitive Landscape and Clinical Trial Analysis 2026 Examines 200+ Companies and 200+ DrugsObesity drug development is shifting to oral, multi-agonist and ultra-long-acting therapies, creating opportunities in less frequent dosing, lean-mass preservation and novel mechanisms.
- Alzheimer's Disease Competitive Landscape and Clinical Trial Analysis Report 2026: More Than 200 Companies and 240 Therapies AssessedAlzheimer’s R&D is shifting toward disease modification, with amyloid, tau, RNA and immune targets driving trials, partnerships and oral therapy opportunities.
- BetterBusinessAdvice.comBest Medical Waste Disposal Company for Dental Offices (2026): Sharps Assure Named a Top Mail-Back Provider by Better Business AdviceBetter Business Advice has named Sharps Assure a top mail-back provider for dental offices, highlighting the company's range of sharps disposal systems, dental amalgam waste solutions, prepaid return services, and disposal documentation. Best...